Industry wide ad revenue in the larger print segment declined 30% to $6.2 billion in the second quarter. Even the smaller online-only segment has not been immune to the recession. According to the NAA, online-only ad revenue fell 16% to about $650 million. Against the backdrop of shrinking demand for products and services, employers grew reluctant to increasing… Read More »
July has been a good month for biotech investors. Share prices in the biotech sector as measured by the NYSE Biotechnology Index are up 24% compared to the 6.6% gain for the S&P 500. Earlier in the month, Amgen (AMGN) reported better-than-expected results from a trial of its experimental bone-protecting drug denosumab in patients with advanced breast cancer.… Read More »
The week past was a noteworthy one for technology investors. Share prices in this sector zoomed higher by 9.4%. After Tuesday’s market close, Intel’s (INTC) second quarter earnings announcement injected life back into the stock market and triggered a bull stampede in many tech names. The Good Intel reported its strongest growth from the first quarter to the… Read More »
Weakness in the U. S. dollar and hopes of an improving global economy have thus far pumped up the price of oil. Oil has nearly doubled in price over the past three months. While oil is taking its cue from the U. S. dollar on a day-to-day basis, the uptrend appears to be running into resistance in recent… Read More »
Although the S&P 500 has advanced 32% since the March 9 market bottom, the rally has been quite selective from a sector perspective. Groups decimated during the recent bear market have rallied the most. Financial shares are up big after losing 81% from September 30, 2007. With investors demonstrating healthy risk appetite, defensive sectors have generally lagged. Utilities… Read More »
This article originally appeared in The Motley Fool on December 14, 2005. Technology companies are generally underappreciated as energy conservation plays. By casting a wider net, investors can find appealing situations in the technology space that stand to prosper from the growing emphasis on energy conservation. Investors typically see oil-related stocks — such as Exxon Mobil (NYSE: XOM)… Read More »
Biotechnology, which has been on a roll, declined after the much-anticipated American Society of Clinical Oncologists meeting in early June in New Orleans, where cancer specialists deliberated on the merits of new treatments. The two extant ETFs which focus on this industry are iShares Nasdaq Biotechnology (AMEX:IBB) and Biotech HOLDRs (AMEX:BBH). Before deciding to dump or load up… Read More »
Investing in biotech stocks has never been for the faint-hearted as many biotech companies have high cash burn rates. The biotech industry however has a few things going for it. Read on to learn more about investment opportunities in this industry. Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting in… Read More »
The favorable dynamics for the Biotechnology industry is attracting investor attention. On the heels of recent gains, there are reasons to be optimistic on continued out-performance. An efficient Food and Drug Administration, progress on extension of new products, trouble in ‘major pharma’ land and reasonable valuation create a favorable milieu for investing in the biotechnology sector. These conditions… Read More »
AlphaProfit’s low risk, low effort investment strategy correctly picks up winners for every market environment. It enables AlphaProfit Premium Service Investment Newsletter and its model portfolios to consistently rank #1 in Hulbert Financial Digest.
Receive Free Reports
Sign up for the FREE investment newsletter AlphaProfit Money Matters and immediately receive Two Special Reports
Five Smart Ways to Profit from Sector Funds and ETFs
Avoid Three Common Mistakes ETF Investors Make
Don’t miss timely investment tips. Stay ahead of the market with AlphaProfit MoneyMatters in your inbox
Premium Service Performance
Model Portfolio Annualized Returns
DEC. 1993 to DEC. 2019
Fidelity Agg. Growth
ETF Agg. Growth
No-Fee Growth (inc. 2009)
Stock Recommendation Returns
DEC. 2013 to DEC. 2019
Avg. Holding Period
DR. SAM SUBRAMANIAN
Sam Subramanian PhD, MBA has credentials that are the envy of most investment advisers. He combines strong quantitative skills with deep financial expertise and insights on inner workings of Wall Street and corporations. His creativity has helped him win 16 U. S. patents.
Prior to founding AlphaProfit Investments, LLC, Sam worked in positions of increasing responsibility in Finance and Corporate Strategy for McKinsey & Company, Exxon Corporation, and Unocal Corporation. His work centered on Acquisitions and Divestitures, Asset Valuation, Trading, Bankruptcies, and Risk Management.
Well aware of the dismal returns produced by money managers, he was determined to take charge of his own investments. He created a low cost, low effort but high return investing system and rigorously tested it for over two decades using his own money.
This high-performance system helped Sam to quickly become financially independent. Sam still invests his money, using the now award-winning system he created. He shares the unbiased, crystal-clear recommendations and market moves with his subscribers.